Alkeus Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 10, 2024

CAMBRIDGE, Mass., Dec. 21, 2023 (GLOBE NEWSWIRE) — Alkeus Pharmaceuticals, Inc. today announced that Joshua Boger, Ph.D., Executive Chairman, and Leonide Saad, Ph.D., President and Chief Executive Officer, will provide a corporate update and present the latest information on its late-stage investigational therapy to prevent blindness, during the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 10, 2024, at 11:30 a.m. PST at The Westin St. Francis Hotel. There will be no live webcast of the presentation.

In addition, Dr. Boger will participate in a panel discussion during Endpoints at #JPM24 on Tuesday, Jan. 9, 2024, at 9:40 a.m. – 10:10 a.m. PST at the San Francisco Marriott Marquis, titled “Biotech Downturn Survival School.”

About Alkeus Pharmaceuticals

Alkeus Pharmaceuticals is a private biopharmaceutical company with headquarters in Cambridge, Mass., backed by institutional investors led by Bain Capital. Founded in 2010, Alkeus is developing therapies for serious diseases of the eye with high unmet need. Alkeus’ breakthrough-designated lead candidate, gildeuretinol (ALK-001), is currently being evaluated in clinical trials for the treatment of Stargardt disease and for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

About Gildeuretinol (ALK-001)

Gildeuretinol was designed by researchers as a novel, specifically deuterated form of vitamin A that reduces vitamin A dimerization, with the potential to slow or halt the progression of vision loss in Stargardt patients without disrupting the visual cycle. In preclinical studies, gildeuretinol decreased vitamin A dimerization by more than 80% and prevented development of blindness in genetic animal models of the disease. A randomized, placebo-controlled, triple-masked clinical trial of gildeuretinol in late-stage Stargardt patients showed clinically and statistically significant slowing of the growth of retinal lesions over two years of treatment. Additional clinical trials of gildeuretinol in Stargardt disease are ongoing, including a fully enrolled, randomized, placebo-controlled, triple-masked, two-year clinical trial in 80 patients with intermediate stage Stargardt disease, with expected readout of topline data in early 2025. In addition, a Phase 3 study of gildeuretinol in 200 patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) has recently been completed and is expected to read out topline data in 2024.

For further information, please contact:

David Setboun, Chief Operating Officer
Email: media01@alkeuspharma.com
Website: www.alkeuspharma.com

Staff

Recent Posts

Empowering Latino Leaders: LCF Georgia’s Second Civic Participation Fellowship Program

LCF Georgia's Civic Participation Fellowship Program: 21 Fellows Trained in Civic Engagement and Community OrganizingATLANTA,…

2 hours ago

Horizon Treatment Services Ushers in a New Era of Inclusion With Drop-in Center for LGBTQIA+ Youth

Safe Haven for Youth and Young AdultsHAYWARD, CA / ACCESSWIRE / June 25, 2024 /…

2 hours ago

Lions Celebrate a Successful Year of Service at the 106th Lions International Convention

OAK BROOK, Ill., June 25, 2024 /PRNewswire/ -- Lions International celebrated several milestones during the…

5 hours ago

INDUSTRY LEADER IN PATIENT CENTRICITY CALLS FOR ITS SYSTEM-WIDE ADOPTION IN NEW BOOK

Dr. Anthony Yanni publishes a wide-ranging case for patient-centered healthcare delivery and treatment development—a "long-overdue…

5 hours ago

CUNY SPH receives $5.2 million NIH grant renewal for cancer genomics research

NEW YORK, June 25, 2024 /PRNewswire/ -- The Informatics Technology for Cancer Research (ITCR) program…

5 hours ago

AliveCor Announces Dual FDA Clearance of AI Technology That Delivers 35 Cardiac Determinations and First-of-its-Kind Kardia 12L ECG System

World's First AI to Detect 35 Cardiac Determinations, Including Heart Attack, Using a Reduced Leadset…

5 hours ago